The appearance of interstitial nephritis is an expected development in the natural history of all forms of progressive renal failure. We have been studying this inflammatory process using an experimental model of immune-mediated interstitial nephritis in mice called anti-tubular basement membrane (alphaTBM) disease. Primary immune injury is produced in this model by T cells and antibodies (alphaTBM-Ab/alpha3M-l-Ab) which are directed at a tubular target antigen (3M-l) expressed by proximal tubular epithelium. Histologic damage occurs through the formation of interstitial mononuclear cell infiltrates that subsequently envoke a progressive fibrogenesis with tubular atrophy. The emergence of this autoimmune process rendering structural damage is a product of complex biochemical events that depend on two interactive components; one component is the development of a destructive nephritogenic immune response. The other component is the reaction of the tubulointerstitium to mononuclear intrusion. The long term purpose and goals of this grant have been focused on the latter issue. In our current renewal we have concentrated selectively on several fundamental, inflammation-relevant protein systems which modulate the immunologic visibility, tissue boundaries, cell size, and phenotype of target tubular epithelium and their associated fibroblasts. Over the course of the last few years our work can be distilled down and tracked into four critical areas: one area has been to determine how MHC class II genes are regulated in tubular epithelium, the second area has been to determine how type IV collagen genes are modulated during basement membrane remodelling, the third area has been to understand the molecular mechanisms of tubular hypertrophy and how cellular enlargement may influence the expression of nephritogenic antigens, and the fourth area has been to develop antibodies and molecular probes which can be used specifically to identify tubulointerstitial fibroblasts. These four project themes collectively bridge the disciplines of genetics and biochemistry with basic pathophysiology in order to better discern major processes leading to aberrant structural change in interstitial tissue. Our experiments rely on both in vitro and in vivo technologies in order to assemble a comprehensive database on this subject; these technologies include the use of cell culture, radioimmunoassay, cDNA cloning, chimeric reporter gene constructs, gel retardation assays, DNA footprinting, transgene replacement, eukaryotic transfection, and antisense inhibition. We believe our approach and the level of our analysis will lead to a better comprehension of critical somatic cell responses to immune events that may offer new insights regarding the formation of rational strategies for improved treatment of interstitial injury.

Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
1996
Total Cost
Indirect Cost
Myers, Jeanne C; Amenta, Peter S; Dion, Arnold S et al. (2007) The molecular structure of human tissue type XV presents a unique conformation among the collagens. Biochem J 404:535-44
Shahan, Tracy; Grant, Derrick; Tootell, Mason et al. (2004) Oncothanin, a peptide from the alpha3 chain of type IV collagen, modifies endothelial cell function and inhibits angiogenesis. Connect Tissue Res 45:151-63
Myers, Jeanne C; Li, Deqin; Amenta, Peter S et al. (2003) Type XIX collagen purified from human umbilical cord is characterized by multiple sharp kinks delineating collagenous subdomains and by intermolecular aggregates via globular, disulfide-linked, and heparin-binding amino termini. J Biol Chem 278:32047-57
Fawzi, A; Robinet, A; Monboisse, J C et al. (2000) A peptide of the alpha 3(IV) chain of type IV collagen modulates stimulated neutrophil function via activation of cAMP-dependent protein kinase and Ser/Thr protein phosphatase. Cell Signal 12:327-35
Shahan, T A; Fawzi, A; Bellon, G et al. (2000) Regulation of tumor cell chemotaxis by type IV collagen is mediated by a Ca(2+)-dependent mechanism requiring CD47 and the integrin alpha(V)beta(3). J Biol Chem 275:4796-802
Pasco, S; Han, J; Gillery, P et al. (2000) A specific sequence of the noncollagenous domain of the alpha3(IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells. Cancer Res 60:467-73
Shahan, T A; Ohno, N; Pasco, S et al. (1999) Inhibition of tumor cell proliferation by type IV collagen requires increased levels of cAMP. Connect Tissue Res 40:221-32
Shahan, T A; Ziaie, Z; Pasco, S et al. (1999) Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. Cancer Res 59:4584-90
Han, J; Jenq, W; Kefalides, N A (1999) Integrin alpha2beta1 recognizes laminin-2 and induces C-erb B2 tyrosine phosphorylation in metastatic human melanoma cells. Connect Tissue Res 40:283-93
Zhang, Y; Niu, Z; Cohen, A J et al. (1999) The internal chondrocyte-specific promoter of the chick type III collagen gene is activated by AP1 and is repressed in fibroblasts by a complex containing an LBP1-related protein. Nucleic Acids Res 27:4090-9

Showing the most recent 10 out of 93 publications